2. Signaling Pathways
  3. Immunology/Inflammation
  4. Macrophage migration inhibitory factor (MIF)
  5. Macrophage migration inhibitory factor (MIF) Inhibitor

Macrophage migration inhibitory factor (MIF) Inhibitor

Macrophage migration inhibitory factor (MIF) Inhibitors (19):

Cat. No. Product Name Effect Purity
  • HY-16692
    ISO-1
    		Inhibitor 99.94%
    ISO-1 is a macrophage migration inhibitory factor (MIF) antagonist with an IC50 of 7 μM.
  • HY-110063
    4-IPP
    		Inhibitor 99.46%
    4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF).
  • HY-17009
    Iguratimod
    		Inhibitor 99.93%
    Iguratimod is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC50 of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod also inhibits macrophage migration inhibitory factor (MIF) with an IC50 of 6.81 μM.
  • HY-147390
    MIF098
    		Inhibitor 99.84%
    MIF098 is a macrophage migration inhibitory factor (MIF) antagonist. MIF098 inhibits proliferation, migration and fibrosis of pulmonary smooth muscle cells. MIF098 can be used for immunoinflammation-related disease research.
  • HY-121356
    Carebastine
    		Inhibitor 99.12%
    Carebastine is the active metabolite of Ebastine. Carebastine is a histamine H1 receptor antagonist. Carebastine inhibits VEGF-induced HUVEC and HPAEC proliferation, migration and angiogenesis in a dose-dependent manner. Carebastine suppresses the expression of macrophage migration inhibitory factor.
  • HY-115887
    R110
    		Inhibitor 99.90%
    R110 is a potent, competitive inhibitor of macrophage migration inhibitory factor 2 (MIF2) tautomerase with an IC50 of 15 μM. R110 has the potential for the research of cancer diseases.
  • HY-W164560
    RDR 03785
    		Inhibitor
    RDR 03785 is a covalent MIF inhibitor with an IC50 of 0.36 μM.
  • HY-123814
    4-CPPC
    		Inhibitor 99.64%
    4-CPPC is a potent, reversible and selective MIF-2 inhibitor with Ki values of 431, 33 µM for MIF-1, MIF-2, respectively.
  • HY-110084
    BTZO-1
    		Inhibitor 99.69%
    BTZO-1 binds to Macrophage migration inhibitory factor (MIF) with a Kd value of 68.6 nM, and its binding requires the N-terminal Pro1. BTZO-1 can activate antioxidant response element (ARE)-mediated gene expression and suppress oxidative stress-induced cardiomyocyte apoptosis in vitro.
  • HY-P99262
    Imalumab
    		Inhibitor
    Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer.
  • HY-144194
    MIF-IN-2
    		Inhibitor
    MIF-IN-2 is a migration inhibitory factor (MIF) inhibitor extracted from patent WO2021258272A1 compound 1. MIF-IN-2 can be used for the research of immune inflammation-related diseases.
  • HY-144196
    MIF-IN-4 hydrochloride
    		Inhibitor
    MIF-IN-4 hydrochloride is potent macrophage migration inhibitory factor (MIF) inhibitor (pIC50=5.01-6). MIF is a cytokine originally found to play a role in inhibiting macrophage migration.
  • HY-146319
    MIF-IN-6
    		Inhibitor
    MIF-IN-6 (compound 2d) is a potent macrophage migration inhibitory factor (MIF) inhibitor with an IC50 of 1.4 μM and a Ki value of 0.96 μM, respectively. MIF-IN-6 attenuates MIF-induced ERK phosphorylation and inhibits proliferation of A549 cells.
  • HY-144190
    MIF-IN-1
    		Inhibitor
    MIF-IN-1 (compound 14) is a potent macrophage migration inhibitory factor (MIF) inhibitor (pIC50=6.87).
  • HY-146318
    MIF-IN-5
    		Inhibitor
    MIF-IN-5 (compound 1d) is a potent and reversible macrophage migration inhibitory factor (MIF) competitive inhibitor with an IC50 of 4.8 μM and a Ki value of 3.3 μM, respectively.
  • HY-130332
    Mitomycin A
    		Inhibitor
    Mitomycin A is a bacterial metabolite. Mitomycin A reduces migration inhibition factor (MIF) production and can be used for the research of cancer.
  • HY-148117
    MD13
    		Inhibitor
    MD13 is a macrophage migration inhibitory factor (MIF)-directed PROTAC with a Ki of 71 nM. MD13 can be used for cancer research.
  • HY-144195
    MIF-IN-3
    		Inhibitor
    MIF-IN-3 is a migration inhibitory factor (MIF) inhibitor extracted from patent WO2021258272A1 compound 31. MIF-IN-3 can be used for the research of immune inflammation-related diseases.
  • HY-149308
    MKA031
    		Inhibitor
    MKA031 (compound 6y) is a non-competitive MIF inhibitor with an IC50 value of 1.7 μM. MKA031 (compound 6y) interferes with MIF/AIF interaction, MIF nuclear translocation, and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced dependent cell death. MKA031 can be used in the study of chronic hepatitis C virus infection.